PMID: 6397449Jan 1, 1984Paper

Recent advances in management of bacterial meningitis in neonates

Infection
J O Klein

Abstract

The current incidence of neonatal sepsis in the United States varies from less than 1 to 8.1 per 1000 live births. The incidence of bacterial meningitis is about one-third of the number of infants with sepsis. The mortality is 20 to 30% and many survivors are severely impaired. Group B streptococcus and Escherichia coli are the most frequent causes of meningitis. Because of the difficulty of clinical diagnosis, many infants receive presumptive therapy for suspected sepsis or meningitis although few have documented infection. Between 5 and 10% of newborn infants born in the United States receive antimicrobial agents in the nursery, usually a penicillin and an aminoglycoside. To lower the continued high mortality and morbidity of meningitis due to gram-negative enteric bacilli, collaborative randomized trials evaluated the efficacy of gentamicin administered via the intrathecal route, gentamicin administered into the ventricle and most recently, the efficacy of moxalactam. Neither intrathecal or intraventricular drug, both in combination with parenteral drug, was advantageous when compared with parenterally administered drug alone. The mortality rate and number of days of culture positive cerebrospinal fluid were similar in infan...Continue Reading

References

Mar 25, 1978·Lancet·A O ShigeokaH R Hill
May 1, 1977·Antimicrobial Agents and Chemotherapy·A DeveikisL Riff
Jan 1, 1978·Scandinavian Journal of Infectious Diseases·D MontefioreE Sobayo
Aug 1, 1976·The Journal of Pediatrics·V SchaufA Serota
Jun 2, 1977·The New England Journal of Medicine·M R HammerschlagR Fermin
Nov 1, 1966·Pediatric Clinics of North America·L GluckM D Fousek
Jun 9, 1983·The New England Journal of Medicine·S P PyatiW I Metzger
Mar 1, 1981·The American Journal of Medicine·C J Baker
Mar 1, 1981·Acta paediatrica Scandinavica·R BennetR Zetterström
Jun 1, 1980·The Journal of Pediatrics·V E Visser, R T Hall

❮ Previous
Next ❯

Citations

Aug 7, 2008·Journal of Cell Science·Takatoshi KarasawaPeter S Steyger
Jan 1, 1989·Acta paediatrica Scandinavica·R BennetR Zetterström
Mar 1, 1992·Clinical Pediatrics·K E Shattuck, T Chonmaitree
Jun 1, 1989·Archives of Disease in Childhood·A H BellM McReid
Jun 1, 1986·British Journal of Addiction·O J Skog
Jan 1, 1987·Scandinavian Journal of Infectious Diseases·R BennhagenA N Békássy
Jan 1, 1988·Journal of Toxicology and Environmental Health·J M SpitsbergenR E Peterson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Meningitis

Bacterial meningitis continues to be an important cause of mortality and morbidity throughout the world. Here is the latest research.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Bacterial Meningitis (ASM)

Bacterial meningitis continues to be an important cause of mortality and morbidity throughout the world. Here is the latest research.

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.